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. The controversy is compounded by rare reports of metastasis 2 . And yet the benign natural history of KA is supported by various studies, including a systematic review of 455 cases with no cases of metastasis or death 1 , and observational studies confirming spontaneous resolution 1 . Unlike in SCC, perineural or venous invasion in KA is not associated with adverse outcome 3, 4 . Comparative genomic hybridisation and DNA microarray studies indicate that KA and SCC are genetically distinct. 5, 6 Some have suggested that the rare reports of metastatic KA may have instead arisen from SCC development within KA 3 .
An online 22-item questionnaire designed by dermatologists and researchers, ascertained clinicians' views about KA and its management, previously observed outcomes and willingness to enrol patients into a proposed clinical trial. While twenty-six (12%) respondents considered KA and SCC to be clinically and histologically indistinguishable, the majority (194, 87%) regarded them as distinct (13%) or likely distinct (74%). Only 28 (13%) felt that conservative management (e.g. clinical observation and/or shave excision) could be considered. Most (166,74%) felt that KA should be managed as for SCC, as spontaneous resolution cannot be reliably predicted nor SCC reliably excluded. Dermatological surgeons were more likely (23%) than dermatologists (10%) or plastic surgeons (0%) (p=0.03) to regard them as indistinguishable.
Twenty-one (9%) reported that they had observed local recurrence of KA, while 4 (2%) reported having observed metastasis.
A photograph of a typical KA-like lesion was presented with three scenarios of lesion behaviour (reducing in size/static/enlarging) over a hypothetical preceding four-week period. For each, respondents could choose multiple management options (see Table 1A ). There were no statistically significant differences between specialties (24 tests all with p>0.05). In the case of the involuting scenario, around 35% selected clinical observation, and around a half excision. When the lesion was static or enlarging, surgical excision was favoured.
The majority (74%, 166) reported not deferring surgery for KA-like lesions while 26% (57) reported doing so, with no significant between-specialty differences apparent (p=0.40). Comments indicated that even if not intended, deferral frequently occurs due to waiting lists. One hundred and forty-two (68%) indicated a willingness to routinely observe KA-like lesions if a clinical trial were to confirm spontaneous resolution in a proportion of cases (Table 2A -supplementary material) .
One hundred and twenty-five (56%) declared that anatomical site did not influence management, although the clinical vignettes indicated a lower inclination to excise involuting lesions on the lower leg compared with the ear.
Over a half indicated willingness to enrol patients with KA-like lesions into a UK multicentre clinical trial (table 1b(i)).
Around a half (Table 1Bii) were willing to enroll patients into a suggested trial design which incorporated a 4-to 5-week initial clinical observation period to establish the growth phase of the lesion, but ensuring risk minimisation by promptly excising all enlarging lesions within 31/62 day NHS cancer targets. Table 1B) .
Suggested exclusion criteria included immunosuppression, genetic disorders (e.g. xeroderma pigmentosum), disputed clinical diagnosis, previous SCC, and high risk or cosmetically sensitive sites (Table 2B -supplementary material).
Inclusion of an initial incisional biopsy reduced clinician willingness to enrol patients. Reasons cited included surgical capacity or duplication of surgery, and concerns over the adequacy of partial biopsy for histological KA diagnosis. (Table 2B - 
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For lesions static in size after 4-5 weeks' observation, 70 (33%) were willing to shave excise, 84 (40%) were not and 57 (27%) were uncertain (Table 1Biv ). Comments highlighted concerns over potential under-treatment of SCC and uncertainty regarding adequacy of shave excision for histological diagnosis. Others indicated a preference for curettage. A proposal to randomise patients with static lesions to either shave or surgical excision did not increase recruitment willingness. (Table 1Bv ).
Ninety (41%) indicated their local histopathologists distinguish KA from SCC, 27 (12%) indicated that they do not and the remainder (101, 46%) noted variation. In a UK histopathology department survey, the ratio of coded SCC to KA varied from 2.5:1 to 139:1 confirming widespread reporting variations 8 . In a clinical trial, centralised expert histopathologist review could overcome this issue. Of note, central review of SCC histology specimens led to reclassification as KA in up to 94.4% of cases in two phase II vemurafenib trials 4 .
Our survey demonstrates significant clinical equipoise in the management of KA-like lesions amongst UK clinicians and confirms a willingness to enrol patients in a clinical trial, while highlighting the need to mitigate against under-treatment of any potential SCC within the trial design.
